Prexige TARGET Study: Not Quite A Bull's-Eye For Novartis
This article was originally published in The Pink Sheet Daily
Executive Summary
The study found a lower risk of gastrointestinal side effects for Prexige compared to ibuprofen and naproxen, but the incidence of serious liver abnormalities was higher for the COX-2 than for the NSAIDs.